RecruitingPHASE1, PHASE2NCT07398508

Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.

Studying Menkes disease

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Stephen G. Kaler
Principal Investigator: Stephen G Kaler, MD, MPH
Columbia University
Intervention: Droxidopa Oral Product(drug)
Enrollment: 6 enrolled
Eligibility: 7-17 years · All sexes
Timeline: 2026 – 2030

Study locations (1)

Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07398508 on ClinicalTrials.gov

Other trials for Menkes disease

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNANCT04337684
Long Term Follow-up on Menkes Disease Patients
Sentynl Therapeutics, Inc.

See all trials for Menkes disease →

← Back to all trials